Nilotinib hcl crystalline forms

A crystalline form of Nilotinib HCl, selected from:

• a) form T1 of Nilotinib HCl characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 5.6, 7.4, 8.9, 10.9 and 20.8 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern having peaks at 7.4, 8.9 and 20.8 degrees two theta±0.2 degrees two theta and at least two more peaks selected from:
• 5.6, 10.9, 11.1, 13.8, 14.1, 21.5, 21.8 and 22.4 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 1;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 2;
• and combinations thereof;
• b) Form T2 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.1, 8.7, 11.5, 14.0, 15.3, 16.6, 17.4, 19.4 and 25.5±0.2 degrees two-theta, an x-ray powder diffraction pattern substantially as depicted in FIG. 3;
• and combinations thereof;
• c) Form T3 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.0, 8.5, 11.4, 12.1, 14.2, 17.2, 19.2, 22.1, 23.2 and 25.3±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 4;
• and combinations thereof;
• d) Form T4 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at about:
• 5.9, 8.8, 11.9, 15.3, 16.6, 19.7, 20.3, 25.4, 26.9 and 27.4±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 5;
• and combinations thereof;
• e) Form T5 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.1, 14.0, 18.4, 20.8, 21.5, 22.5, 24.8, 25.4 and 27.3±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 6;
• and combinations thereof;
• f) Form T6 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.2, 8.8, 14.4, 22.3, 23.4, 25.7, 26.4, 27.7, 29.6 and 31.5±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 7;
• and combinations thereof;
• g) Form T7 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 3.8, 7.5, 18.7, 19.9, and 25.4 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 8;
• and combinations thereof;
• h) Form T8 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 6.5, 7.4, 18.3, 23.1 and 24.3 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 9;
• and combinations thereof;
• i) Form T9 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 8.7, 9.4, 12.2, 17.4, 18.1, 19.4, 22.2, 24.1, 25.1, 25.8 and 26.2±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 10;
• and combinations thereof;
• j) Form T10 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 8.9, 14.0, 21.0, 23.8 and 25.6 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 11;
• and combinations thereof;
• k) Form T11 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.4, 8.7, 17.4, 25.3, 26.2 and 35.1±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 12;
• and combinations thereof;
• l) Form T12 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.4, 9.5, 12.3, 14.8, 15.9, 19.4, 19.8, 22.3, 24.3 and 25.9±0.2 degrees two-theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 13;
• and combinations thereof;
• m) Form T13 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 8.2, 12.8, 15.7, 16.5, 21.7 and 23.9±0.2 degrees two-theta;
• an x-ray powder diffraction substantially as depicted in FIG. 14;
• and combinations thereof;
• n) Form T14 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 7.5, 7.9, 8.7, 19.4 and 25.3 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 15;
• and combinations thereof;
• o) Form T15 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 6.3, 7.3, 8.6, 12.2 and 18.2 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 16;
• and combinations thereof;
• p) Form T16 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 8.1, 9.0, 14.1, 18.0 and 21.4 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 17;
• and combinations thereof;
• q) Form T18 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 5.5, 7.2, 8.7, 9.6 and 10.9 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern having peaks at 5.5, 7.1, 8.7, 9.6 and 10.9 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 23;
• and combinations thereof;
• and
• r) Form T19 of Nilotinib HCl, characterized by data selected from:
• an x-ray powder diffraction pattern having peaks at 5.5, 7.2, 9.2, 9.6 and 10.9 degrees two theta±0.2 degrees two theta;
• an x-ray powder diffraction pattern substantially as depicted in FIG. 24;
• and combinations thereof.